Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Nov;7(4):201-9.
doi: 10.1007/s11904-010-0057-1.

Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation

Sarit A Golub  1 , Don Operario, Pamina M Gorbach
Affiliations
Review

Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation

Sarit A Golub et al. Curr HIV/AIDS Rep. 2010 Nov.

Abstract

Pre-exposure prophylaxis (PrEP) has the potential to become a powerful biomedical approach to HIV prevention; however, its success depends on behavioral and social factors that may determine its appropriate use. This article is designed to facilitate interdisciplinary empirical analogies relevant to PrEP implementation, reviewing behavioral and social science findings that may provide lessons critical to the success of PrEP as a biomedical-behavioral prevention strategy. As we prepare for the dissemination of new biomedical approaches to HIV prevention, integrating the state of the science across disciplines may result in innovative strategies for implementation that can enhance their success.

PubMed Disclaimer

References

    1. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48:806–815. doi: 10.1086/597095. - DOI - PMC - PubMed
    1. Vissers DC, Voeten HA, Nagelkerke NJ, et al. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS ONE. 2008;3:e2077. doi: 10.1371/journal.pone.0002077. - DOI - PMC - PubMed
    1. CDC: HIV/AIDS Surveillance Report, 2004. Atlanta: US Department of Health and Human Services; 2005.
    1. Grant RM. Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis. 2010;50(Suppl 3):S96–S101. doi: 10.1086/651479. - DOI - PMC - PubMed
    1. UNAIDS &AIDS Vaccine Advocacy Coalition. Good participatory practice: Guidelines for biomedical HIV prevention trials. Geneva, Switzerland: 2007.

Substances